Poster 23
- Kelley Tangredi
- May 27, 2024
- 1 min read
Updated: Jun 27, 2024
Efficacy and Safety of Lebrikizumab is Maintained to Two Years in Patients with Moderate-to-Severe Atopic Dermatitis
Authors: Emma Guttman-Yassky, Stephan Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan Silverberg, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaci
Poster 23